Since Denosumab is as effective as bisphosphonates which are the current standard of care for osteoporosis and other bone resorption diseases8, an active anti-RANKL immunotherapy would be a viable strategy for the treatment of osteoporosis and other bone related diseases. Here, TNFSF11 is linked to osteoporosis.